Posted by Lamdage22 on October 2, 2014, at 13:53:12
In reply to Re: New drug developments, posted by Lamdage22 on October 1, 2014, at 12:58:25
I received this email from Naurex:
Julian
Thank you for your interest. Naurexs human clinical studies are currently focused in the area of depression. We believe the drugs in our research and development pipeline have high potential as therapies for other diseases as well. We are currently conducting early-stage research of our compounds across a number of psychiatric and neurologic conditions. We hope to begin human clinical studies in these areas in the near future. Please continue to check clinicaltrials.gov
http://clinicaltrials.gov/ct2/results?term=Naurex&Search=Search
as well as the Naurex website
www.naurex.com
for more information on ongoing clinical trials.
Best regards,
Naurex Inc.
From: Julian **********
Sent: Sunday, September 21, 2014 7:11 AM
To: Naurex Corporate
Subject: Glyx-13 open label schizophrenia/schizo-affective
Name: Julian *******
E-Mail: **************
Subject: Glyx-13 open label schizophrenia/schizo-affectiveMessage: Can you notify me if you conduct an open label study for schizo-affective or schizophrenic patients with Glyx-13?
Is anything like this planned?
Thank you,
JulianSo we have those links to watch:
http://clinicaltrials.gov/ct2/results?term=Naurex&Search=Search
http://clinicaltrials.gov/ct2/results?term=glyx-13&Search=Search
http://clinicaltrials.gov/ct2/results?term=nrx-1074&Search=Searchwww.naurex.com
One of those studies, funded by Northwestern University, that is currently recruiting is for schizophrenics and schizo-affective patients. I hope it will come out with a statement as to wether or not these two compounds can be utilized in schizoid-disorders without a too big risk (or maybe without any risk at all?) of causing psychosis. Unfortunately MAO Inhibitors are poison for people prone to psychosis.
Literally, even if they are, along with Remeron, to my mind the only antidepressants that could improve depression and negative symptoms in most of these patients. This is very unfortunate. And with the introduction of Naurex´s two lead compounds, we just may have much better news for people who are both depressed and prone to psychosis and/or affected by negative schizophrenia symptoms + the inherent propensity toward psychosis.
Speaking of psychosis, Anandamide based treatments are much further away unfortunately.
But even they will eventually come. I hope that research will start off soon and we can watch it coming closer and closer to us, the patients, just like Glyx-13 and NRX1074.
So the bottom line is: Hang in there!
Schizophrenia and Depression
Seroquel 800mg
Zyprexa 5mg
Lithium orotate 480mg
Metformin 1500mg
Effexor 20mg
poster:Lamdage22
thread:1071665
URL: http://www.dr-bob.org/babble/20140914/msgs/1071749.html